AlphAIAlphAI — Financial news for AI agents
investing.comOCT 111 min read$CARG

CarGurus CTO Quinn sells $113,266 in shares

CarGurus CTO Matthew Todd Quinn sold 3,824 shares at $29.62 each, totaling $113,266. He also had 9,129 shares withheld for taxes. Quinn now owns 220,193 shares. CarGurus reported Q2 earnings of $0.66 per share on $251M revenue, beating estimates. Needham raised its price target to $44, maintaining a Buy rating.

Original reporting
investing.com
Published Oct 11, 2026, 10:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 4:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$CARG
Neutral
high confidence
Mentioned
$CARG
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CARGNeutralLow
01

Why it matters

The insider sale is a minor, routine disclosure with limited trading impact, especially given the positive earnings backdrop.

02

Market read

The article combines a routine insider sale with recent earnings beat; the sale alone offers little actionable insight.

03

What to watch

Recent strong earnings and AI product rollout may offset any minor sell pressure.

Relevance 4/10Novelty 3/10Timing: post‑sale reporting

Background

CarGurus reported robust Q2 results and raised its full‑year outlook, while the CTO executed a pre‑planned share sale.

Company-level read

Ticker impact

$CARGNeutralHigh confidence
Context

CTO Quinn sold 3,824 shares under a 10b5‑1 plan, a routine insider sale disclosed for the first time.

Expected impact

potential slight pressure as market prices in the insider sale

Evidence & confidence

The sale size ($113k) is modest and typical for 10b5‑1 plans, unlikely to move the stock significantly.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The insider sale could be a routine liquidity event, not a negative signal.

Key entities

  • Company
    CarGurus, Inc.

    Online automotive marketplace (NASDAQ:CARG).

  • Executive
    Matthew Todd Quinn

    Chief Technology Officer of CarGurus.

Read at source← All news

Related articles

AUG 6
$CARGLow

CarGurus Announces Second Quarter 2026 Results

CarGurus, Inc. (CARG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CarGurus Announces Second Quarter 2026 Results Q2'26 revenue grew 13% YoY to $251.0 million, above the midpoint of our guidance range Q2'26 GAAP net income from continuing operations of $49.2 million; non-GAAP adjusted EBITDA from continuing operations of $84.7 milli

SEC EDGAR 8-K6 min
JUN 3
$ACVAMedAI 8/10

ACV Auctions, CarGurus, and LendingTree Shares Are Falling, What You Need To Know

Stocks including ACV Auctions, CarGurus and LendingTree fell after higher Treasury yields compressed valuations for growth names, while geopolitical uncertainty weighed on advertising expectations, according to the article. ACV Auctions dropped 6.4% after a GAAP loss of $0.14/share and weaker Q4 revenue and EBITDA guidance. Meta rose about 3% on an enterprise AI agent launch and an analyst upgrade.

markets.financialcontent.com6 min
OCT 27
$AZNMed

AstraZeneca delays PACIFIC-9 lung cancer trial data to H1 2027

Innate Pharma (IPH, IPHA) announced AstraZeneca (AZN) delayed the PACIFIC-9 trial data to H1 2027 from H2 2026, citing the study's event-driven nature. The trial tests durvalumab with monalizumab or oleclumab in Stage III lung cancer. Monalizumab is co-developed by Innate and AZN. Innate Pharma is a clinical-stage biotech listed in Paris and on Nasdaq.

investing.com1 min